Nitrous

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitrous

Property Description
Active Ingredient Isosorbide Dinitrate
Form Oral tablets, Sublingual tablets, Sustained-release preparations
Pharmacological Class Antianginal Agent, Vasodilator
General Purpose Reduces heart workload by widening blood vessels
Origin Synthetic, Organic Nitrate

Nitrous is the specific trade name for a medicine whose active substance is Isosorbide Dinitrate, a prescription-only, synthetic compound classified as an Organic Nitrate drug. It belongs to the broad clinical class of Antianginal Agents and acts fundamentally as a vasodilator, with a primary role of widening blood vessels. As a synthetic compound, its structure contains two nitrate functional groups, and its mechanism involves acting as a precursor to nitric oxide (NO) within the body.

Forms of Delivery and General Therapeutic Purpose

Isosorbide Dinitrate is manufactured in several high-level dosage forms, including standard oral tablets and fast-acting sublingual tablets, as well as specialized sustained-release preparations. The inclusion of the sublingual route of administration is a key differentiating feature, clinically recognized for allowing rapid absorption into the bloodstream when a swift onset of action is necessary. The variety of forms ensures the medicine can be utilized for systemic effect.

The drug's general therapeutic purpose is directly derived from its powerful vasodilator properties: to reduce the overall workload on the heart. By relaxing blood vessels, particularly the veins (venodilation), Isosorbide Dinitrate decreases the volume of blood returning to the heart, easing the pressure. The administration of nitrates is a recognized approach for reducing cardiac work and improving blood supply to the heart muscle. This action helps maintain a better balance between the heart muscle's requirement for oxygen and the available blood supply, which is the essential function of an Antianginal Agent.

Regulatory References

  1. Isosorbide: MedlinePlus Drug Information
  2. Isosorbide Dinitrate - StatPearls - NCBI Bookshelf

What side effects are possible with Nitrous?

Possible Side Effects and Safety Information

The safety profile of Isosorbide Dinitrate (Nitrous) is characterized by effects predominantly related to its potent blood vessel widening action. Adverse reactions are formally classified by frequency according to international regulatory standards, with incidence often related to the initial exposure.


Officially Documented Adverse Reactions

The most common adverse effects are concentrated in the Nervous System and Vascular system, as detailed in regulatory documents.

Classification Representative Adverse Reactions
Very Common (ge1 in 10) Headache (often throbbing)
Common (ge1 in 100 to <1 in 10) Dizziness, Orthostatic Hypotension (low blood pressure upon standing), Asthenia (weakness), Reflex Tachycardia
Uncommon (ge1 in 1,000 to <1 in 100) Nausea, Vomiting, Flushing, Syncope (fainting)

Serious Reactions and Safety Constraints

The regulatory safety text documents serious adverse reactions, notably the risk of Severe Hypotensive Responses and Paradoxical Bradycardia (unusually slow heart rate) accompanying profound low blood pressure. Rare occurrences of Methaemoglobinaemia are noted in the context of overdose.

Time-Related Patterns: Headache incidence is officially noted to diminish gradually with continued use. Hypotension and dizziness are typically observed more commonly at the beginning of treatment or following a dose increase.

Safety Restrictions: A strict contraindication exists for concurrent use with Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) and Riociguat, due to the substantial risk of severe, life-threatening hypotension. Caution is also required for use in older adults and those with severe hepatic or renal impairment, as documented in official labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Nitrous (Isosorbide Dinitrate) results from an exaggerated extension of its vasodilatory action, which can lead to severe physiological consequences. Documented manifestations cited in regulatory information include a prompt fall in blood pressure (hypotension), persistent and throbbing headache, tachycardia, bradycardia, vertigo, syncope, and visual disturbances. Gastrointestinal effects such as nausea, vomiting, and bloody diarrhea have also been cited.

Severe or life-threatening outcomes can include Circulatory Collapse, Respiratory Failure, and a specific complication known as Methemoglobinemia, which may lead to cyanosis.

Immediate medical attention must be sought if an overdose is suspected, as hospitalization, potentially in an Intensive Care Unit (ICU), is required. Treatment is directed toward increasing central fluid volume using methods such as passive elevation of the patient's legs or intravenous infusion of normal saline. While no specific antagonist to the primary vasodilator effects is known, Methylene Blue is the specific treatment listed for Methemoglobinemia. Invasive monitoring may be required for patients with pre-existing renal disease or congestive heart failure during supportive care.

Therapeutic Uses of Nitrous

This medication is relevant for easing symptoms associated with specific heart conditions, serving as a core component of symptomatic support. The drug is commonly used to help manage two main therapeutic areas: Angina Pectoris (chest pain) and certain symptomatic manifestations of Chronic Heart Failure (CHF).


Symptom Relief and Therapeutic Benefits

The primary role of this medicine is to address symptoms related to Ischemic Chest Pain, such as the pressure or heaviness that can appear suddenly, particularly during periods of exertion or stress. It is also applied in clinical settings to provide supportive relief during acute episodes of pain and may be part of symptomatic management for reducing the risk of episodic or fluctuating manifestations. This use contributes to improved comfort during periods of heightened symptoms.

The drug is also applied across domains where additional symptomatic support is needed, notably as an adjunct therapy in Chronic Heart Failure (CHF). It is considered relevant for managing symptom clusters that create noticeable physiological strain, like those related to fluid congestion. This use contributes to improved day-to-day comfort during symptomatic periods.


“It is used in situations involving certain distressing symptoms, offering symptomatic relief that helps patients cope more steadily.”


Quick Fact: Relief for Angina Pectoris This medication is primarily used to help manage the discomfort of chest pain, supporting the patient during difficult episodes and assisting with maintaining functional comfort.

Regulatory References

  1. NIH MedlinePlus overview of Isosorbide

Eligibility and Restrictions for Use

Who Can and Cannot Use Isosorbide Dinitrate

Official regulatory documents define specific population eligibility rules for the use of Isosorbide Dinitrate. The medicine is primarily permitted for Adults who are using it for approved indications and have no documented contraindications.


Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults with approved indications who have no documented contraindications or conditions requiring restriction.

Populations for whom use is contraindicated: Patients with known hypersensitivity to any organic nitrate; Patients concurrently using Phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil); Patients concurrently using the soluble guanylate cyclase (sGC) stimulator riociguat; Patients with severe hypotension.

Age-related eligibility rules: Use is not established in pediatric patients (under 18 years of age); Use is allowed in older adults (geriatric patients), but caution is advised due to potential susceptibility to hypotensive effects.

Condition-specific eligibility rules: Use requires caution in patients with severe hepatic impairment, severe renal impairment, hypertrophic cardiomyopathy, or those who are volume depleted.

Pregnancy and lactation eligibility status (if explicitly documented): For pregnancy, use is classified as Category C (use only if benefit justifies potential risk to fetus). Caution is advised during lactation.

What should I know about interactions with other medicines?

The interaction profile for Isosorbide Dinitrate is fundamentally structured by Absolute Contraindications, prohibiting co-administration with specific medicinal products.

  • Contraindicated Combinations: Co-administration is formally contraindicated with Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat). This prohibition is based on the documented risk of severe hypotension, syncope, or myocardial ischemia due to the potentiated vasodilatory effects.
  • Pharmacodynamic Potentiation: The profile includes multiple instances of additive effects. Concomitant use with other Vasodilators, Blood Pressure Lowering Agents (e.g., Beta-blockers, ACE Inhibitors, Calcium Antagonists), and certain other classes like Neuroleptics and Tricyclic Antidepressants may potentiate the hypotensive effect according to regulatory documentation.
  • Exposure Modification and Substance Interaction: An interaction is documented with Dihydroergotamine, as co-administration may lead to an increase in the blood level of Dihydroergotamine and enhance its hypertensive effect. The official profile also includes an additive interaction with Alcohol (Ethanol), which may potentiate the hypotensive response.
  • Population Constraints: Regulatory documents advise caution for use in patients with severe hepatic or renal impairment, as these conditions are officially noted to affect the drug’s metabolic and clearance profile, thereby altering its interaction relevance.

Mechanism of Action

Nitrous oxide is an inhalational agent that quickly enters the bloodstream and partitions into the central nervous system. The primary mechanism of action involves the modulation of the N-methyl-D-aspartate ( NMDA) receptor. Specifically, N2 O functions as a non-competitive NMDA receptor antagonist, binding within the ion channel pore in a voltage-dependent manner. This interaction inhibits the excitatory neurotransmission pathway mediated by the amino acid glutamate, thereby reducing neuronal excitability. Downstream consequences include the modulation of synaptic plasticity and signal transduction pathways involved in nociception. Furthermore, N2 O interacts with GABA-A receptors and two-pore domain potassium (K2P) channels. The GABA-A receptor interaction promotes inhibitory signaling, while the modulation of specific K2P channels may contribute to hyperpolarization. Collectively, these molecular interactions lead to a systemic alteration of central neurotransmission, modulating the physiological processing of pain and arousal.

Dosage and Administration Information

How Nitrous (Isosorbide Dinitrate) is Used in Clinical Practice

Isosorbide Dinitrate is administered through multiple approved routes, including oral (immediate-release and extended-release tablets), sublingual, and intravenous infusion. The choice of route depends on the required onset of action for the treatment plan. For chronic prophylaxis, the immediate-release oral form is typically started at a dose range of 5 mg to 20 mg two or three times daily, adjusted up to a maintenance range of 10 mg to 40 mg.

Dosing Schedule and The Dose-Free Interval

The central principle governing the long-term use of this medicine is the mandatory daily dose-free interval. To minimize the development of pharmacological tolerance, clinical protocols for chronic regimens, regardless of the formulation used, incorporate a period of at least 14 to 18 hours without the drug. This requirement structures the dosing schedule, preventing continuous exposure.

Administration Specifics

Form Administration Instructions
Oral IR Tablets Preferably taken on an empty stomach.
Sublingual Tablets Must be placed under the tongue and allowed to dissolve; they must not be swallowed or chewed. The dosage is typically 2.5 mg to 5 mg and can be repeated every 5 to 10 minutes, not exceeding three doses in a short interval.
Extended-Release Must be swallowed whole; the integrity of the tablet or capsule must not be compromised by crushing or chewing.

For older adults, the official guidance is to initiate therapy at the low end of the recommended adult dosing range.

Recent Clinical Evidence

Research Evidence for Angina Pectoris

Research was studied for its use in research exploring how symptoms change over time related to chest pain, a condition characterized by episodic manifestations. These investigations include Randomized Controlled Trials (RCTs) and systematic reviews that research examined in adult populations with stable angina. Studies monitored how the compound was evaluated in exploring how the compound affects the frequency of pain episodes. The fast-acting forms were studied in research exploring short-term symptom changes during periods of increased symptom activity.

Research examined outcomes monitoring physiological strain or stress, such as documentation of changes in the frequency of angina episodes and the use of emergency rescue medication. Studies report how symptoms evolved in the observed populations, where the medicine was associated with documented changes in exercise capacity and a different pattern in the frequency of reported angina episodes in some study groups.


Research Evidence for Chronic Heart Failure (CHF)


The role of this medicine was evaluated in research exploring Chronic Heart Failure (a condition marked by functional limitations) primarily as an adjunct therapy in combination with hydralazine. These investigations include large-scale, Randomized, Placebo-Controlled Trials (RCTs) that often observed responses over defined time intervals of a year or more, tracking serious outcomes such as death from any cause and rates of hospitalization for heart failure exacerbations.

Data show patterns related to outcomes where certain populations receiving the combination therapy was associated with a difference in the incidence of all-cause mortality and rates of hospitalization for heart failure exacerbations when compared to placebo groups in the specific conditions under which they were conducted. The primary evidence base in heart failure is derived from studies of the fixed-dose combination with hydralazine; comparative evidence for Isosorbide Dinitrate used alone in this setting is lacking.


What is Still Uncertain About Nitrous Research

Research highlights that while certain patterns have been observed, evidence quality varies across studies, and certainty remains low regarding some findings. Observations related to nitrate tolerance have been reported across multiple studies; data show patterns related to how the medicine's activity may be influenced by administration schedules. Additionally, as background treatments for heart conditions have evolved, comparative evidence is lacking against other established therapies.

Key Studies & References

  1. Isosorbide Dinitrate: MedlinePlus Drug Information (General Monograph)

Frequently Asked Questions (FAQ)

Common questions about Nitrous (FAQ)


Q: Does Nitrous affect the ability to drive or operate machinery afterward?

Regulatory documents caution that this medicine may cause dizziness, lightheadedness, or fainting. For this reason, official safety information states that driving, operating machinery, or performing tasks requiring alertness should be avoided until an individual understands how the medicine affects them.


Q: Does Nitrous interact with common pain relievers like ibuprofen?

The official interaction profile lists various medications that may have an additive effect, including those that affect blood pressure. While specific common pain relievers may not be individually listed in the general class warnings, consultation with a healthcare professional is necessary for a review of all medicines, including over-the-counter pain relievers, before starting treatment.


Q: Can taking anti-anxiety medication interfere with Nitrous?

Regulatory safety information indicates that combining this medicine with other agents that lower blood pressure, which may include certain anti-anxiety or psychiatric drugs, could strengthen the hypotensive effect. Consultation with a healthcare provider is recommended for review of all medications before starting this medicine.


Q: Can pregnant individuals receive Nitrous during certain procedures?

This medicine is classified as Pregnancy Category C according to regulatory standards. Official guidance states that use during pregnancy is advised only if the potential benefit justifies the potential risk to the fetus, based on a medical professional's assessment.


Q: Is the onset of Nitrous rapid or slow?

The speed at which the medicine begins to work varies by how it is administered. For a swift action, the sublingual form is designed to be fast-acting. In contrast, the standard oral and extended-release tablets have a slower onset and are intended for long-term management.


Q: Is Nitrous available for home use, and what are the rules around that?

Isosorbide Dinitrate is a prescription medicine that is typically self-administered by the patient following a prescribed regimen. Official patient information indicates that the medicine should be stored according to specific rules, for example, by keeping it in its original, tightly closed container, protected from excessive heat and moisture, and always out of the sight and reach of children.


Q: Is Nitrous the same thing as general anesthesia?

No, these are distinct. Isosorbide Dinitrate is a vasodilator used to ease the heart’s workload. Nitrous Oxide ( N2 O) is an inhaled gas used for pain relief and mild to moderate sedation, but official guidelines state that it is not classified as general anesthesia when used alone in approved concentrations.


Q: How quickly does the effect of Nitrous wear off?

The duration of effect varies with the formulation used. Immediate-release tablets provide effects for a shorter time. The extended-release form, which is intended for prevention, can maintain its effect for a longer period, sometimes up to 8 to 12 hours, but this is dependent on the specific dose and adherence to the required drug-free interval.


Q: Are there different types of Nitrous administration systems?

Yes, there are different forms and administration methods. The medicine Isosorbide Dinitrate is manufactured as oral, sublingual, and extended-release tablets. Nitrous Oxide ( N2 O) is delivered via specialized gas mixer devices (flowmeters) that allow the gas mixture to be inhaled by the patient.


Q: Is it true that Nitrous can be used for things other than dental work?

Yes. Isosorbide Dinitrate is approved for conditions related to heart health, specifically to prevent chest pain (angina) and as part of combination therapy for chronic heart failure. Nitrous Oxide ( N2 O) is also approved for use as a pain reliever and sedative in various medical procedures outside of dentistry, such as in emergency care or labor and delivery.


Q: Do I need to fast or stop eating before receiving Nitrous?

Instructions for the immediate-release oral tablets state that they are preferably taken on an empty stomach. The fast-acting sublingual tablets must also be allowed to dissolve under the tongue without eating, drinking, or chewing at the time of administration.


Q: How long can the effects of Nitrous last after it stops being given?

The active compound and its main breakdown products can remain in the body for several hours, with half-lives ranging from approximately 1 to 5 hours. This is relevant to the mandatory daily drug-free interval of at least 14 to 18 hours, which is necessary for chronic use to minimize the development of tolerance.


Q: Does using Nitrous affect memory of the procedure?

For Nitrous Oxide ( N2 O) used for sedation, official reports note that it may cause feelings of euphoria and dissociation, which can alter a patient’s perception and memory of the event. However, it is not primarily intended to cause full memory loss (amnesia) when used in approved conscious sedation protocols.


Q: What is the difference between Nitrous and oxygen used in hospitals?

They are two distinct medical agents. Nitrous (Isosorbide Dinitrate) is an organic nitrate drug that works as a vasodilator to help widen blood vessels. Oxygen is an essential medical gas that is often supplied to patients separately or combined with inhaled drugs, such as Nitrous Oxide ( N2 O), to ensure safe respiratory function.


Q: Are there long-term health concerns related to medical use of Nitrous?

Regulatory safety information highlights that a key issue with long-term use is the potential for pharmacological tolerance, which is why a daily drug-free interval is mandatory. The primary long-term considerations noted in official labeling are related to the prevention of pharmacological tolerance, as well as risks such as Methaemoglobinaemia, typically noted in the context of overdose, and the risk of severe hypotension.


Q: Why is the gas mixture usually combined with oxygen?

Nitrous Oxide ( N2 O) is delivered as a gas mixture combined with oxygen to maintain the patient's breathing safety. Official guidelines specify a minimum concentration of oxygen in the blend to help ensure the patient maintains safe oxygen levels and avoids hypoxia.


Q: How does the sensation of receiving Nitrous usually feel?

The sensations vary by the form of the drug. Patients using Isosorbide Dinitrate commonly report a headache or flushing (warmth/redness) due to the blood vessel widening effect. Those receiving Nitrous Oxide ( N2 O) for sedation often describe temporary feelings of euphoria or dissociation.


Q: What happens if I accidentally swallow Nitrous instead of inhaling it?

The fast-acting sublingual tablets are designed to be absorbed sublingually and are not to be swallowed. Swallowing the tablet is noted in official instructions as a practice that will reduce or delay the intended fast onset of the medicine's effects.


Q: What is the purpose of the 'scavenging system' used with Nitrous?

Regulatory guidelines describe the purpose of the scavenging system, an accessory attached to Nitrous Oxide ( N2 O) delivery equipment, as safely collecting and removing waste analgesic gases from the immediate breathing area of the patient and the treatment room, which helps to control occupational exposure for healthcare personnel.


Q: Does the intensity of the effects change based on the dose used?

Yes. Official regulatory labeling documents the use of different initial and maintenance dosing ranges for this medicine. This is in line with the general pharmacological principle that both the therapeutic benefits and the potential for adverse reactions are typically dose-related.


Q: Why is Nitrous sometimes called 'laughing gas'?

This common nickname refers only to Nitrous Oxide ( N2 O). This term originated because the gas is documented to sometimes induce feelings of temporary euphoria or mild giddiness in patients receiving it for pain relief.


Q: How do medical professionals monitor a patient receiving Nitrous?

Monitoring protocols vary by drug. For Nitrous Oxide ( N2 O) conscious sedation, official guidelines describe monitoring procedures where staff confirm the patient remains conscious and continues to breathe spontaneously. For Isosorbide Dinitrate, monitoring primarily involves observing blood pressure and checking for signs of a severe hypotensive response, particularly when treatment begins.


Q: Is it normal to feel a tingling sensation when using Nitrous?

Yes. Official safety information documents that flushing is a commonly reported side effect of Isosorbide Dinitrate. Flushing is often described as feelings of warmth, redness, or a tingly sensation in the skin, which is related to the medicine's primary action of widening blood vessels.


Q: Is the gas flammable or explosive?

Regulatory safety data confirms that Nitrous Oxide ( N2 O) is not considered flammable itself. However, it is classified as an oxidizing agent and can actively support combustion, meaning it can accelerate the burning rate of flammable materials nearby.


Q: Can a person talk while receiving Nitrous?

Yes. Nitrous Oxide ( N2 O) is used for conscious sedation, which is a state where the patient is minimally depressed. Official guidelines confirm that a key requirement of this type of sedation is that the patient retains the ability to communicate and respond to verbal commands.


Q: Is it possible to become fully unconscious from Nitrous alone?

When Nitrous Oxide ( N2 O) is administered in approved concentrations for minimal sedation, the goal is to maintain a state where the patient remains conscious and responsive. The official guidelines describe a level of sedation where the patient retains the ability to respond to command, indicating that unintended full unconsciousness is generally not expected.


Q: Are there specific situations where the effects of Nitrous might be reduced?

Yes. Regulatory documents note that the effects of the drug may be reduced over time if there is continuous exposure, a phenomenon known as nitrate tolerance (or tachyphylaxis). Official instructions specify the need for patients on chronic therapy to adhere to a daily drug-free interval.


Q: How is Nitrous different from IV sedation?

Nitrous Oxide ( N2 O) is an inhaled gas that produces minimal to moderate sedation, which wears off rapidly once administration stops. In contrast, IV sedation involves medications administered directly into the vein, resulting in a typically deeper level of sedation that is less quickly reversible by simply ceasing drug delivery.


Q: What regulatory bodies oversee the medical use of Nitrous?

The medical use of this medicine is controlled by official regulatory bodies in each country. These include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada, who are responsible for approving the medicine's indications, safety warnings, and official labeling.


Q: Is there a maximum time limit for using Nitrous during a single procedure?

Regulatory information for a single administration does not specify a maximum time limit. However, the efficacy documented in studies for the sustained-release form can last up to 8 hours. Official labeling emphasizes the need for adherence to a daily drug-free interval for chronic therapy to prevent the development of tolerance.

How should Nitrous be stored and disposed of?

Storage and Disposal of Isosorbide Dinitrate

Isosorbide Dinitrate tablets must be stored according to regulatory requirements to preserve product stability.

Storage Requirements

The medication must be maintained at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F). The tablets require protection from excessive heat and moisture, and official labeling advises against storage in the bathroom. Sublingual forms must also be protected from light. The medicine must remain in its original container, which must be kept tightly closed.

Safety and Disposal

Always store the medication out of the sight and reach of children. Unused or expired tablets should not be flushed down the toilet or poured into a drain. Disposal must follow authorized governmental guidelines, which include returning the product to a drug take-back program or utilizing specific procedures for household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitrous found in:

A-Z Index: